The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
November 28, 2022
Maribavir (Livtencity) for Cytomegalovirus Infection (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Maribavir (Livtencity) for Cytomegalovirus Infection (online only)
November 28, 2022 (Issue: 1664)
Maribavir (Livtencity – Takeda), an oral cytomegalovirus
(CMV) pUL97 kinase inhibitor, has been
approved by the FDA for treatment of post-transplant
CMV infection refractory to standard antiviral therapy
in patients ≥12 years old who weigh at...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.